Inclusion

Inclusion Criteria for Transplant:

• Diagnosis of non-Hodgkin's lymphoma, transformed B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse large B-cell or T-cell lymphoma, and deemed a candidate for autologous transplant
• Signed informed consent
• Male patient agrees to use an adequate method of contraception for the duration of the study
• Renal: Creatinine clearance (calculated creatinine clearance is permitted) > 40 mL/min
• Pulmonary: DLCO, FEV1, and FVC >= 50% of predicted (corrected for hemoglobin)
• Hepatic: Bilirubin =< 2.0 mg/dL (except for isolated hyperbilirubinemia attributed to Gilbert syndrome) and ALT and AST =< 3x the upper limit of normal
• Cardiac: American Heart Association Class I: Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain. Additionally, patients > 60 years of age must have a left ventricular ejection fraction of at least >= 40% demonstrated by MUGA or Echo
• Autologous graft with a minimum of >= 3.0 x 10^6 CD34+ cells/kg (not CD34 selected)
• Female patients of childbearing potential has a negative serum pregnancy test beta-hCG
• Female patient is either post menopausal, free from menses for >= 2 years, surgically sterilized, or willing to use 2 adequate barrier methods of contraception to prevent pregnancy or agrees to abstain from heterosexual activity throughout the study

Inclusion Criteria for Maintenance Therapy:

• 30-120 days post ASCT for non-Hodgkin's lymphoma: CrCL >= 40 mL/min; PLT >= 75,000, and ANC >= 1500 cells/mm3 for 5 days after recovery from ASCT nadir; TB =< 2.0 (unless history of Gilbert's disease), AST/ALT =< 2.5 x ULN

Exclusion

Exclusion Criteria for Transplant:

• Karnofsky performance score < 70%
• Uncontrolled bacterial, viral, or fungal infection (currently taking medication and with progression or no clinical improvement)
• Pregnant or breastfeeding
• Fertile men and women unwilling to use contraceptive techniques from the time of transplant until one month post maintenance therapy
• Prior autologous or allogeneic HSCT
• Patients with evidence of MDS/AML or abnormal cytogenetics analysis indicative of MDS on the pre-transplant bone marrow examination
• Prolonged QTC on EKG
• Poorly-controlled DM
• Prior history of HIV positivity or known history of hepatitis B or C
• Previous history of hypersensitivity to Bortezomib, boron, or mannitol; known hypersensitivity to the components of study drug or its analogs
• Require therapeutic anticoagulation treatment, especially with coumadin
• Patient who has had chemotherapy, radiotherapy, or biological therapy, within 30 days (42 days for nitrosoureas or mitomycin C) or who has not recovered from adverse events due to agents administered more than 30 days earlier
• Patient is currently participating or has participated in a study with an investigational compound or devise within 30 days of initial dosing with study drug(s)
• History of CNS disease
• Patient had prior treatment with an HDAC inhibitor (e.g., romidespin (Depsipeptide), NSC-630176, MS 275, LAQ-824, belinostat (PXD-101), LBH589, MGCD0103, CRA024781, etc)
• Patients who have received compounds with HDAC inhibitor-like activity, such as valproic acid, as anti-tumor therapy should not enroll in this study; patients who have received such compounds for other indications (e.g., valproic acid for epilepsy) may enroll after a 30-day washout period
• Symptomatic ascites or pleural effusions
• Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
• Patient is, at the time of signing informed consent, a regular user of any illicit drugs, substance abuse or had a recent history (within the last year) of drug or alcohol abuse
• Patient with a history of a prior malignancy with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma or an in situ malignancy; adequately treated localized prostate carcinoma with PSA < 1.0; or who has undergone potentially curative therapy with no evidence of disease for five years, and/or who is deemed at low risk for recurrence by his/her treating physician
• Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study or is not in the best interest of the patient to participate
• Patient has a history of a gastrointestinal surgery or other procedures that might, in the opinion of the investigator, interfere with the absorption or swallowing of the study drugs

Exclusion Criteria for Maintenance Therapy:

• MI with ASCT or developed dilated cardiomyopathy with ASCT
• Untreated systemic infection
• K and Mg < normal limits of adequate supplementation
• >= grade 2 peripheral neuropathy within 14 days before beginning maintenance therapy
• Any other non-study investigational agent; radiation therapy will not be allowed
• Prolonged QTC
• Poorly controlled DM